{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:24:16Z","timestamp":1790645056803,"version":"4.1.0"},"reference-count":33,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T00:00:00Z","timestamp":1682985600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2023,5,2]]},"abstract":"<jats:p>Background: Alzheimer\u2019s disease (AD) biomarkers reflect key elements of pathophysiology and improve the diagnostic process. However, their use in routine clinical practice is still limited. Objective: We aimed to assess neurologists' barriers and enablers to early AD diagnosis using core AD biomarkers. Methods: We conducted an online study in collaboration with the Spanish Society of Neurology. Neurologists answered a survey exploring their attitudes towards AD diagnosis using biomarkers in mild cognitive impairment (MCI) or mild AD dementia. Multivariate logistic regression analyses were conducted to determine the association between neurologists\u2019 characteristics and diagnostic attitudes. Results: We included 188 neurologists with a mean age (SD) of 40.6 (11.3) years, 52.7% male. Most participants had access to AD biomarkers, mainly in cerebrospinal fluid (CSF) (89.9%,#x0025;, n\u200a=\u200a169). The majority of participants (95.2%,#x0025;, n\u200a=\u200a179) considered CSF biomarkers useful for an etiological diagnosis in MCI. However, 85.6% of respondents (n\u200a=\u200a161) used them in less than 60% of their MCI patients in routine clinical practice. Facilitating patients and their families to plan for the future was the most frequent enabler for the use of biomarkers. Short consultation time and practicalities associated with the programming of a lumbar puncture were the most common barriers. A younger neurologist age (p\u200a=\u200a0.010) and a higher number of patients managed weekly (p\u200a=\u200a0.036) were positively associated with the use of biomarkers. Conclusion: Most neurologists had a favorable attitude to the use of biomarkers, especially in MCI patients. Improvements in resources and consultation time may increase their use in routine clinical practice.<\/jats:p>","DOI":"10.3233\/jad-221160","type":"journal-article","created":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T12:34:47Z","timestamp":1679661287000},"page":"275-282","source":"Crossref","is-referenced-by-count":15,"title":["Attitudes of Neurologists Toward the Use of Biomarkers in the Diagnosis of Early Alzheimer\u2019s Disease"],"prefix":"10.1177","volume":"93","author":[{"given":"Juan","family":"Fortea","sequence":"first","affiliation":[{"name":"Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain"},{"name":"Biomedical Research Institute Sant Pau, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"},{"name":"Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Garc\u00eda-Arcelay","sequence":"additional","affiliation":[{"name":"Medical Department, Roche Farma, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngeles","family":"Terrancle","sequence":"additional","affiliation":[{"name":"Medical Department, Roche Farma, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"G\u00e1lvez","sequence":"additional","affiliation":[{"name":"Medical Department, Roche Diagnostics, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ver\u00f3nica","family":"D\u00edez-Carreras","sequence":"additional","affiliation":[{"name":"Medical Department, Roche Farma, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Rebollo","sequence":"additional","affiliation":[{"name":"IQVIA, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Maurino","sequence":"additional","affiliation":[{"name":"Medical Department, Roche Farma, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia-Ribas","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-221160_ref1","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/alz.12694","article-title":"Global estimates on the number of persons across the Alzheimer\u2019s disease continuum","volume":"19","author":"Gustavsson","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-221160_ref2","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s13195-020-00723-1","article-title":"Health-related quality of life in people with predementia Alzheimer\u2019s disease, mild cognitive impairment or dementia measured with preference-based instruments: A systematic literature review","volume":"12","author":"Landeiro","year":"2020","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-221160_ref3","doi-asserted-by":"crossref","first-page":"719","DOI":"10.3233\/JAD-220696","article-title":"Quality of life and the experience ofliving with early-stage Alzheimer\u2019s disease","volume":"90","author":"Villarejo-Galende","year":"2022","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-221160_ref4","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-221160_ref5","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","article-title":"Clinical diagnosis of Alzheimer\u2019s disease: Recommendations of the International Working Group","volume":"20","author":"Dubois","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-221160_ref6","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-221160_ref7","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3389\/fneur.2020.00496","article-title":"Potential new approaches for diagnosis of Alzheimer\u2019s disease and related dementias","volume":"11","author":"Turner","year":"2020","journal-title":"Front Neurol"},{"key":"10.3233\/JAD-221160_ref9","doi-asserted-by":"crossref","first-page":"e12314","DOI":"10.1002\/dad2.12314","article-title":"Clinical application of CSF biomarkers for Alzheimer\u2019s disease: From rationale to ratios","volume":"14","author":"Bouwman","year":"2022","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.3233\/JAD-221160_ref10","doi-asserted-by":"crossref","first-page":"e026380","DOI":"10.1136\/bmjopen-2018-026380","article-title":"What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France","volume":"9","author":"Cognat","year":"2019","journal-title":"BMJ Open"},{"key":"10.3233\/JAD-221160_ref11","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jalz.2014.06.006","article-title":"The use of biomarkers for theetiologic diagnosis of MCI in Europe: An EADC survey","volume":"11","author":"Bocchetta","year":"2015","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-221160_ref12","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3233\/JAD-170443","article-title":"Prediction and early detection of Alzheimer\u2019s dementia: Professional disclosure practices and ethical attitudes","volume":"62","author":"Schweda","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-221160_ref13","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/gps.5427","article-title":"Biomarker counseling, disclosure of diagnosis andfollow-up in patients with mild cognitive impairment: A European Alzheimer\u2019s disease consortium survey","volume":"36","author":"Frederiksen","year":"2021","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.3233\/JAD-221160_ref14","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3233\/JAD-200884","article-title":"Views on early diagnosis of Alzheimer\u2019s disease among dutch physicians: A qualitative interview study","volume":"79","author":"Tromp","year":"2021","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-221160_ref15","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jocn.2019.08.013","article-title":"Therapeutic nihilism of neurological diseases: A comparative qualitative study","volume":"69","author":"Sedney","year":"2019","journal-title":"J Clin Neurosci"},{"key":"10.3233\/JAD-221160_ref16","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12875-019-0956-1","article-title":"General practitioners\u2019 attitudes towards early diagnosis of dementia: A cross-sectional survey","volume":"20","author":"Giezendanner","year":"2019","journal-title":"BMC Fam Pract"},{"key":"10.3233\/JAD-221160_ref18","doi-asserted-by":"crossref","first-page":"e0134038","DOI":"10.1371\/journal.pone.0134038","article-title":"Thinking styles and regret in physicians","volume":"10","author":"Djulbegovic","year":"2015","journal-title":"PLoS One"},{"key":"10.3233\/JAD-221160_ref19","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1037\/a0027445","article-title":"Evaluating the properties of the Evidence-Based Practice Attitude Scale (EBPAS) in health care","volume":"24","author":"Melas","year":"2012","journal-title":"Psychol Assess"},{"key":"10.3233\/JAD-221160_ref20","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/joim.12752","article-title":"Physician burnout: Contributors, consequences and solutions","volume":"283","author":"West","year":"2018","journal-title":"J Intern Med"},{"key":"10.3233\/JAD-221160_ref21","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/MLR.0b013e318280f02c","article-title":"Validation of a 10-item care-related Regret Intensity Scale (RIS-10) for health care professionals","volume":"51","author":"Courvoisier","year":"2013","journal-title":"Med Care"},{"key":"10.3233\/JAD-221160_ref22","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1007\/s11606-014-3112-6","article-title":"Using a single item to measure burnout in primary care staff: A psychometric evaluation","volume":"30","author":"Dolan","year":"2015","journal-title":"J Gen Intern Med"},{"key":"10.3233\/JAD-221160_ref23","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12798"},{"key":"10.3233\/JAD-221160_ref24","doi-asserted-by":"crossref","first-page":"592302","DOI":"10.3389\/fneur.2020.592302","article-title":"Early stages of Alzheimer\u2019s disease: Evolving the care team for optimal patient management","volume":"11","author":"Galvin","year":"2021","journal-title":"Front Neurol"},{"key":"10.3233\/JAD-221160_ref25","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3233\/JAD-191253","article-title":"What could be the main levers to promote a timely diagnosis of neurocognitive disorders","volume":"75","author":"Garnier-Crussard","year":"2020","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-221160_ref26","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1002\/alz.12756","article-title":"The Alzheimer\u2019s Association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease","volume":"18","author":"Hansson","year":"2022","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-221160_ref27","first-page":"197","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"10.3233\/JAD-221160_ref28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-221160_ref29","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1177\/1471301218761911","article-title":"Communicating a diagnosis of dementia: A systematic mixed studies review of attitudes and practices of health practitioners","volume":"18","author":"Low","year":"2019","journal-title":"Dementia (London)"},{"key":"10.3233\/JAD-221160_ref30","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s40120-022-00366-4","article-title":"Therapeutic decision-making under uncertaintyin the management of spinal muscular atrophy: Results fromDECISIONS-SMA Study","volume":"11","author":"Saposnik","year":"2022","journal-title":"Neurol Ther"},{"key":"10.3233\/JAD-221160_ref31","doi-asserted-by":"crossref","first-page":"e197093","DOI":"10.1001\/jamanetworkopen.2019.7093","article-title":"Comonparis of physician therapeutic inertia for management of patients with multiple sclerosis in Canada, Argentina, Chile, and Spain","volume":"2","author":"Almusalam","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.3233\/JAD-221160_ref32","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s12603-010-0265-9","article-title":"Assessing physician attitudes and perceptions of Alzheimer\u2019s disease across Europe","volume":"14","author":"Martinez-Lage","year":"2010","journal-title":"J Nutr Health Aging"},{"key":"10.3233\/JAD-221160_ref33","doi-asserted-by":"crossref","first-page":"e2250921","DOI":"10.1001\/jamanetworkopen.2022.50921","article-title":"Analysis of psychological symptoms following disclosure of amyloid-positron emission tomography imaging results to adults with subjective cognitive decline","volume":"6","author":"Caprioglio","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.3233\/JAD-221160_ref34","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.trci.2019.02.008","article-title":"Reconsidering frameworks of Alzheimer\u2019s dementia when assessing psychosocial outcomes","volume":"5","author":"Gaugler","year":"2019","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.3233\/JAD-221160_ref35","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1080\/13607863.2019.1566811","article-title":"Psychological predictors of \u2018living well\u2019 with dementia: Findings from the IDEAL study","volume":"24","author":"Lamont","year":"2020","journal-title":"Aging Ment Health"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-221160","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:07:31Z","timestamp":1777370851000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-221160"}},"subtitle":[],"editor":[{"given":"Ayda","family":"Rostamzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,5,2]]},"references-count":33,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3233\/jad-221160","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,2]]}}}